Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Stocker

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
The Journal of Gene Medicine|July 28, 2009
Single-dose lentiviral gene transfer for lifetime airway gene expressionAlice G Stocker, Karlea L Kremer, Rachel Koldej, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
SAGA-a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinomaB Kobitzsch, G Stocker, U T Hacker, et al.
ESMO Gastrointestinal Oncology|April 30, 2026
UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA)G Stocker, U T Hacker, R Lordick Obermannová, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trialR Stelmach, S Lorenzen, T J Ettrich, et al.
Ophthalmology|April 1, 1990
Clinical management of keratoconus. A multicenter analysisJ H Lass, R G Lembach, S B Park, et al.
ESMO Open|June 4, 2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trialG Stocker, S Lorenzen, T Ettrich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 2024
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE studyF Lordick, M E Mauer, G Stocker, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
The Journal of Gene Medicine|July 28, 2009
Single-dose lentiviral gene transfer for lifetime airway gene expressionAlice G Stocker, Karlea L Kremer, Rachel Koldej, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
SAGA-a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinomaB Kobitzsch, G Stocker, U T Hacker, et al.
ESMO Gastrointestinal Oncology|April 30, 2026
UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA)G Stocker, U T Hacker, R Lordick Obermannová, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trialR Stelmach, S Lorenzen, T J Ettrich, et al.
Ophthalmology|April 1, 1990
Clinical management of keratoconus. A multicenter analysisJ H Lass, R G Lembach, S B Park, et al.
ESMO Open|June 4, 2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trialG Stocker, S Lorenzen, T Ettrich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 14, 2024
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE studyF Lordick, M E Mauer, G Stocker, et al.
Pageof 3